The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus
Marc Y Donath and Thomas Mandrup-Poulsen*
Correspondence *Department for Translational Diabetology, Steno Diabetes Center, 2 Niels Steensensvej, DK-2820 Gentofte, Denmark
Email tmpo@steno.dk
Although the mechanisms of 
-cell failure in type 2 diabetes mellitus remain debated, islet inflammation is implicated and the cytokine interleukin-1 has emerged as a master regulator of this process. The potential role of anakinra—a recombinant human IL-1-receptor antagonist—in the treatment of type 2 diabetes mellitus is discussed.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
